Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SAT1 | P21673 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13213181 | 1.00 | TDP1 (0.36) | TDP1L3MBTL1SAT1SIGMAR1 | |
| SCHEMBL13165399 | 0.86 | SAT1 (0.39) | TDP1L3MBTL1SAT1SIGMAR1 | |
| SCHEMBL273581 | 0.86 | — | — | |
| SCHEMBL6019205 | 0.86 | SAT1 (0.39) | TDP1L3MBTL1SAT1SIGMAR1 | |
| SCHEMBL14639713 | 0.85 | — | — | |
| SCHEMBL12527756 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL1165197 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL23212665 | 0.80 | — | — | |
| SCHEMBL8888333 | 0.79 | NCF1 (0.42) | TDP1L3MBTL1SAT1SIGMAR1 | |
| SCHEMBL14416207 | 0.79 | NCF1 (0.42) | TDP1L3MBTL1SAT1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| US-8865865-B2 | N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2014-10-21 | — | — | US | disclosed |
| EP-2349312-B1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS UNIVERSITÄT MARBURG (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010048941-A2 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | TDP1 1287/4885L3MBTL1 4359/4885SAT1 2052/4885 |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | TDP1 1089/4885L3MBTL1 349/4885SAT1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.